Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $26.1 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 28.2% year-over-year to $26.1 million in Q1 2026; TTM through Mar 2026 was $97.3 million, a 21.57% increase from a year earlier, with the FY2025 full-year figure at $91.6 million, up 13.86% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $26.1 million, up from $25.0 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for SUPN reached as high as $26.1 million in Q1 2026 and fell as low as $18.8 million in Q4 2024.
• Historically, Depreciation & Amortization (CF) has averaged $21.7 million across 5 years, with a median of $21.4 million in 2025.
• Across the five-year window, Depreciation & Amortization (CF) soared 226.22% in 2022 and slipped 13.06% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $20.8 million in 2022, then grew by 3.97% to $21.7 million in 2023, then retreated by 13.06% to $18.8 million in 2024, then soared by 32.75% to $25.0 million in 2025, then increased by 4.46% to $26.1 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $26.1 million in Q1 2026, $25.0 million in Q4 2025, and $24.8 million in Q3 2025.